[1]何金品,石 拓,陈星星.益气活血消痞法对慢性萎缩性胃炎胃癌前病变的影响研究[J].陕西中医,2022,(8):1032-1036.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.010]
　HE Jinpin,SHI Tuo,CHEN Xingxing.Clinical study on the treatment of chronic atrophic gastritis with precancerous lesions by Yiqi Huoxue Xiaopi method[J].,2022,(8):1032-1036.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.010]
点击复制

益气活血消痞法对慢性萎缩性胃炎胃癌前病变的影响研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年8期
页码:
1032-1036
栏目:
临床研究
出版日期:
2022-08-05

文章信息/Info

Title:
Clinical study on the treatment of chronic atrophic gastritis with precancerous lesions by Yiqi Huoxue Xiaopi method
作者:
何金品; 石 拓; 陈星星
(武汉市中西医结合医院消化内科,湖北 武汉 430033)
Author(s):
HE Jinpin; SHI Tuo; CHEN Xingxing
(Department of Gastroenterology,Wuhan Hospital of Integrated Traditional Chinese and Western Medicine,Wuhan 430033,China)
关键词:
慢性萎缩性胃炎;  胃癌前病变;  益气活血消痞法;  血管内皮生长因子;  表皮细胞生长因子
Keywords:
Chronic atrophic gastritis;  Precancerous lesions of gastric cancer;  Yiqi Huoxue Xiaopi method;  Vascular endothelial growth factor;  Epidermal growth factor
分类号:
R 573.32
DOI:
DOI:10.3969/j.issn.1000-7369.2022.08.010
文献标志码:
A
摘要:
目的:探讨慢性萎缩性胃炎(CAG)治疗中,中医益气活血消痞法的应用效果及对胃癌前病变的临床作用。方法:随机将80例CAG患者分为两组,每组40例。以接受根治幽门螺杆菌(HP)四联疗法联合安慰剂治疗者为常规组,以接受根治HP四联疗法联合益气活血消痞法治疗者为观察组,两组治疗时间均为12周。分析两组治疗过程中中医证候分级量化积分、胃黏膜病理性积分、外周血T淋巴细胞亚群、白细胞介素及细胞生长因子水平的变化情况。并对比两组12周治疗完成后的临床治疗效果及不良反应发生率。结果:在12周的治疗时间内,两组中医证候分级量化总评分均呈降低趋势(P<0.05)。治疗8周及治疗12周后,观察组中医证候分级量化总评分低于对照组(P<0.05)。两组病理积分治疗前比较差异无统计学意义(P>0.05),12周治疗完成后,观察组低于对照组(P<0.05)。在12周的治疗时间内,两组CD8+、白细胞介素4(IL-4)、白细胞介素6(IL-6)及表皮细胞生长因子(EGF)水平均呈降低趋势,CD4+、CD4+/CD8+、白细胞介素2(IL-2)、血管内皮生长因子(VEGF)及一氧化氮(NO)水平均呈升高趋势(P<0.05); 治疗8周及治疗12周后,观察组CD8+、IL-4、IL-6、EGF水平均低于对照组,CD4+、CD4+/CD8+、IL-2、VEGF及NO水平均高于对照组(P<0.05)。接受12周治疗后,观察组治疗总有效率高于对照组(P<0.05); 且两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:CAG治疗中,益气活血消痞法对胃癌前病变有较好的临床效果。
Abstract:
Objective:To explore the application effect of traditional Chinese medicine in the treatment of chronic atrophic gastritis(CAG)and its blocking and reversing effect on precancerous lesions of gastric cancer.Methods:Using randomly number method,80 CAG patients were divided into two groups,each group contained 40 patients.Patients who received radical treatment of Helicobacter pylori(HP)quadruple therapy combined with TCM decoction placebo were treated as the control group,and those who received radical treatment of HP quadruple therapy combined with TCM decoction Yiqi Huoxue Xiaopi method were treated as the observation group.The treatment time of both groups was 12 weeks.The changes of TCM syndrome grading score,pathological score of gastric mucosa,T lymphocyte subsets,interleukin and cell growth factor levels in peripheral blood of the two groups during treatment were analyzed.The clinical therapeutic effect and the adverse treatment reaction were compared between the two groups after 12 weeks of treatment.Results:In 12 weeks of treatment,the quantitative total score of TCM syndrome grading showed a decreasing trend in both groups(P<0.05).After 8 weeks and 12 weeks of treatment,the total quantitative score of TCM syndrome grading in the observation group was lower than control group(P<0.05).Before treatment,there was no significant difference in pathological score between two groups(P>0.05).After 12 weeks of treatment,the pathological score of the observation group was lower than control group(P<0.05).Within 12 weeks of treatment,the levels of CD8+,IL-4,IL-6 and EGF were decreased,while the levels of CD4+,CD4+/CD8+,IL-2,VEGF and NO were increased(P<0.05).After 8 weeks and 12 weeks of treatment,the levels of CD8+,IL-4,IL-6 and EGF in the observation group were lower than control group,the levels of CD4+,CD4+/CD8+,IL-2,VEGF and NO were higher than those in the control group(P<0.05).After 12 weeks of treatment,the total effective rate of observation group was higher than control group(P<0.05).There was no statistical difference of adverse treatment reaction between the two groups(P>0.05).Conclusion:In the treatment of CAG,the TCM method of Yiqi Huoxue Xiaopi method has significant blocking and reversing effects of PLGC.

参考文献/References:

[1] 张青蓝,孟冬月,张一冲,等.同时性多发早期胃癌的危险因素及预后分析[J].现代消化及介入诊疗,2021,26(10):1310-1313.
[2] 王亚杰,国 嵩,杨 洋,等.慢性萎缩性胃炎的流行病学及其危险因素分析[J].中国中西医结合消化杂志,2019,27(11):874-878.
[3] 于 爽,孔令梅,蒲 玉.莫沙比利联合复方铝酸铋治疗慢性萎缩性胃炎的临床效果[J].国际老年医学杂志,2022,43(1):73-75.
[4] 陈 佳,李守英,徐 红.慢性萎缩性胃炎的研究进展[J].中国老年学杂志,2013,33(14):3540-3542.
[5] 李赛鹤,刘 力,王捷虹,等.基于“和”法探究中医药治疗慢性萎缩性胃炎[J].陕西中医,2020,41(6):793-795.
[6] 吴焕淦,朱 璐,刘慧荣,等.灸法治疗胃肠疾病的效应机制研究[J].世界中医药,2022,17(3):287-294,303.
[7] 中国中西医结合学会消化系统疾病专业委员会.慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):121-131.
[8] 国家食品药品监督管理总局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2022:125-129.
[9] 吴水清,李达周,龚清全,等.福建宁德地区慢性萎缩性胃炎与幽门螺旋杆菌感染情况调查研究[J].陕西医学杂志,2020,49(6):763-765,769.
[10] 曹 阳,顾巍杰,杨德才,等.基于临床流调的慢性萎缩性胃炎发病危险因素研究[J].世界科学技术-中医药现代化,2020,22(4):1060-1067.
[11] 吴水清,黄建成,李达周,等.OLGA及OLGIM分期系统对1790例慢性萎缩性胃炎患者胃癌风险的评估价值[J].陕西医学杂志,2021,50(6):756-758.
[12] 王 苏,蒋俊艳,郑紫丹.胃蛋白酶原的个体含量差异及对慢性萎缩性胃炎和早期胃癌鉴别诊断的价值[J].河北医药,2017,39(19):2930-2932,2935.
[13] 李修荣,李军茹.慢性萎缩性胃炎患者血清miR-129和miR-32水平与疾病发生风险的关系[J].河北医药,2019,41(23):3547-3550.
[14] 马 婷,王品昊,朱 婕,等.行健汤联合穴位贴敷治疗进展期胃癌癌因性疲乏疗效及对患者免疫功能的影响[J].陕西中医,2020,41(10):1410-1413.
[15] 时小红,周利民.慢性萎缩性胃炎诊疗思想认识及基础研究[J].中华全科医学,2019,17(10):1687-1690,1707.
[16] 胡乃军,王海龙.胃腺癌组织中MMP-11、MMP-12和VEGF-D的表达及临床意义[J].陕西医学杂志,2019,48(5):554-556,560.
[17] 秦和平,易 平.胃微生态和胃部疾病及胃黏膜免疫关系研究进展[J].中国医药导报,2021,18(17):45-47,57.
[18] 张 鹏,于 勇,万 强,等.补虚养胃汤加减治疗慢性萎缩性胃炎疗效及对患者胃肠功能的影响[J].陕西中医,2022,43(1):66-68.
[19] 白 敏,成映霞,段永强,等.香砂六君子汤对慢性萎缩性胃炎大鼠胃黏膜相关因子水平的影响[J].中国中医药信息杂志,2020,27(11):52-57.
[20] 寇 媛,闻新丽,薛 峰.养胃清热化瘀汤治疗慢性萎缩性胃炎及癌前病变临床研究[J].陕西中医,2021,42(9):1233-1235,1298.

相似文献/References:

[1]孙明明,李 聪,史 林.王庆国教授对慢性萎缩性胃炎的治疗经验探析[J].陕西中医,2019,(2):260.
　SUN Mingming,LI Cong,SHI Lin..Analysis on the treatment experience of chronic atrophic gastritis by professor WANG Qingguo[J].,2019,(8):260.
[2]钱元霞,汤玲珺,钱 祯,等.四逆散对慢性萎缩性胃炎癌前病变大鼠的作用及机制研究*[J].陕西中医,2019,(8):990.
　QIAN Yuanxia,TANG Lingjun,QIAN Zhen,et al.The effect of Sinisan on the rats of precancerous lesion of chronic atrophic gastritis and its mechanism[J].,2019,(8):990.
[3]闫 强,杨国强 △.健脾清胃汤治疗脾胃虚弱型慢性萎缩性胃炎疗效及对患者免疫功能的影响[J].陕西中医,2019,(8):1014.
　YAN Qiang,YANG Guoqiang..Effect of Jianpi Qingwei decoction on chronic atrophic gastritis of spleen and stomach deficiency and its influence on patients' immune function[J].,2019,(8):1014.
[4]杨宏升.安胃活血汤联合序贯法治疗慢性萎缩性胃炎胃癌前病变疗效研究[J].陕西中医,2019,(9):1195.
　YANG Hongsheng..Effect of Anwei Huoxue decoction combined with sequential therapy on gastric precancerous lesions of chronic atrophic gastritis[J].,2019,(8):1195.
[5]马佳乐 ,李慧臻.中医治疗慢性萎缩性胃炎研究进展*[J].陕西中医,2019,(11):1646.
　MA Jiale,LI Huizhen..Traditional Chinese medicine in the treatment of chronic atrophic gastritis[J].,2019,(8):1646.
[6]曾微微,麦联任,张 玲,等.健胃益脾汤治疗慢性萎缩性胃炎疗效及对患者胃蛋白酶原的影响*[J].陕西中医,2020,(11):1548.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.008]
　ZENG Weiwei,MAI Lianren,ZHANG Ling,et al.Effect of Jianwei Yipi decoction on treating chronic atrophic gastritis and its influence on pepsinogen[J].,2020,(8):1548.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.008]
[7]王 阳.基于络病理论探析慢性萎缩性胃炎“气络失和,毒损血络”病机*[J].陕西中医,2020,(11):1632.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.030]
　WANG Yang..Analysis of pathogenesis of chronic atrophic gastritis based on collateral disease theory[J].,2020,(8):1632.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.030]
[8]张紫涵,陈 俊,徐 丹.苦参碱联合胃复春片治疗慢性萎缩性胃炎疗效及对患者血清胃蛋白酶原亚群的影响[J].陕西中医,2021,(3):323.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.013]
　ZHANG Zihan,CHEN Jun,XU Dan.Effect of matrine combined with Weifuchun tablet on efficacy and serum pepsinogen subgroup in patients with chronic atrophic gastritis[J].,2021,(8):323.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.013]
[9]寇 媛,闻新丽,薛 峰.养胃清热化瘀汤治疗慢性萎缩性胃炎及癌前病变临床研究[J].陕西中医,2021,(9):1233.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.021]
　KOU Yuan,WEN Xinli,XUE Feng.Clinical study on Yangwei Qingre Huayu decoction in treatment of chronic atrophic gastritis and precancerous lesions[J].,2021,(8):1233.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.021]
[10]张 鹏,于 勇,万 强,等.补虚养胃汤加减治疗慢性萎缩性胃炎疗效及对患者胃肠功能的影响[J].陕西中医,2022,(1):66.[doi:DOI:10.3969/j.issn.1000-7369.2022.01.016]
[11]孔维枝,相宏杰,张海东,等.名中医曹志群基于“虚、瘀、毒”理论防治慢性萎缩性胃炎“炎、癌”转化经验[J].陕西中医,2023,(10):1443.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.025]
　KONG Weizhi,XIANG Hongjie,ZHANG Haidong,et al.Professor Cao Zhiqun's experience of preventing and treating “inflammation cancer transformation” of chronic atrophic gastritis from the aspects of deficiency,stasis and poison[J].,2023,(8):1443.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.025]

备注/Memo

备注/Memo:
基金项目:湖北省卫生健康委员会卫生健康科研项目(WJ2021W071); 武汉市临床医学科研重点项目(中医药及中西医结合类)(WZ20A07)
更新日期/Last Update: 2022-08-10